Kilitch Drugs (India) Ltd

Kilitch Drugs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Kilitch Drugs (India) Ltd

₹ 175 -2.43%
14 Jul - close price
kilitch.com BSE: 524500 NSE: KILITCH
About

Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products[1]

Key Points

Business Overview:[1]
KDL is a pharmaceutical company engaged in developing, manufacturing, marketing, and exporting various Pharmaceutical Formulations in dosage forms like Solid, Liquid, and Parental.

Website BSE NSE - BE
  • Market Cap ₹ 612 Cr.
  • Current Price ₹ 175
  • High / Low ₹ 250 / 117
  • Stock P/E 20.3
  • Book Value ₹ 80.0
  • Dividend Yield 0.00 %
  • ROCE 14.4 %
  • ROE 12.5 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has delivered good profit growth of 60.0% CAGR over last 5 years
  • Company's median sales growth is 28.4% of last 10 years

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 11.4% over last 3 years.
  • Company has high debtors of 186 days.
  • Promoter holding has decreased over last 3 years: -4.48%
  • Working capital days have increased from 71.9 days to 130 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
45 37 41 32 45 33 47 56 61 43 49 54 90
39 30 33 30 38 32 41 47 47 40 44 48 67
Operating Profit 6 6 9 2 7 2 6 9 15 3 5 6 22
OPM % 14% 17% 21% 7% 16% 5% 13% 16% 24% 8% 10% 11% 25%
1 1 0 3 0 3 5 2 2 3 7 2 0
Interest 1 2 2 2 1 2 0 1 2 2 1 1 1
Depreciation 1 1 1 1 1 1 1 1 1 1 1 1 1
Profit before tax 5 5 7 3 5 2 10 8 14 3 9 6 20
Tax % 43% 33% 25% 38% 31% 93% 17% 32% 26% 34% 14% 23% 26%
3 3 5 2 4 0 9 6 10 2 8 4 15
EPS in Rs 1.05 0.99 1.35 0.83 1.03 0.38 2.46 1.70 2.97 0.87 2.34 1.27 4.15
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
19 21 27 51 82 53 68 114 140 154 198 235
21 25 28 45 75 53 63 104 122 130 167 199
Operating Profit -2 -4 -1 6 7 0 5 10 18 24 32 37
OPM % -9% -19% -2% 11% 9% 1% 8% 9% 13% 16% 16% 16%
3 2 1 3 4 4 3 3 3 4 11 11
Interest 0 0 0 0 1 1 1 1 5 6 5 6
Depreciation 2 10 10 2 2 2 2 2 4 3 3 4
Profit before tax -1 -12 -9 6 9 2 5 10 12 19 34 39
Tax % -70% -4% -5% 16% 55% 48% 27% 35% 31% 30% 28% 24%
-0 -11 -9 5 4 1 4 6 8 14 25 30
EPS in Rs -0.10 -3.89 -3.09 1.72 1.15 0.25 1.09 2.17 3.08 4.17 7.63 8.63
Dividend Payout % 0% 0% 0% 13% 20% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 27%
5 Years: 28%
3 Years: 19%
TTM: 19%
Compounded Profit Growth
10 Years: 17%
5 Years: 60%
3 Years: 45%
TTM: 26%
Stock Price CAGR
10 Years: 26%
5 Years: 18%
3 Years: 26%
1 Year: -26%
Return on Equity
10 Years: 6%
5 Years: 10%
3 Years: 11%
Last Year: 13%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 13 13 13 14 15 15 15 16 16 16 16 35
Reserves 107 95 88 98 106 103 112 124 136 160 186 245
0 0 1 1 9 13 15 20 22 32 49 89
7 8 11 15 13 12 61 50 46 32 61 89
Total Liabilities 127 117 113 128 144 143 203 210 220 240 313 458
9 42 33 33 32 32 30 65 64 62 64 67
CWIP 0 0 1 3 20 30 65 3 4 6 47 140
Investments 72 49 53 56 53 52 60 71 62 72 72 75
46 25 26 35 38 30 47 71 90 100 129 176
Total Assets 127 117 113 128 144 143 203 210 220 240 313 458

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-8 17 1 1 0 4 46 6 3 -2 18 24
-31 -20 -2 -4 -14 -10 -38 -15 8 -8 -40 -100
-0 0 -0 6 17 1 2 7 -1 9 13 82
Net Cash Flow -39 -2 -0 2 3 -5 10 -2 10 -1 -9 6
Free Cash Flow -10 -26 -0 -2 -19 -6 9 -2 -1 -8 -29 -76
CFO/OP 430% -442% -202% 25% 60% 1,598% 877% 79% 39% 23% 82% 94%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 243 286 196 148 86 109 122 132 142 149 156 186
Inventory Days 124 110 84 39 36 70 35 28 10 18 53 33
Days Payable 124 154 184 108 33 89 525 239 200 118 189 230
Cash Conversion Cycle 243 241 96 79 89 89 -367 -79 -48 50 20 -11
Working Capital Days 197 234 115 93 37 22 -223 -40 -4 30 56 130
ROCE % -10% -9% 5% 6% 1% 3% 6% 10% 13% 16% 14%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Number of Permanent Employees
employees ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Cephalosporin Share of Standalone Revenue
% ・Standalone data
General Injectable Share of Standalone Revenue
% ・Standalone data
Number of Countries Served
countries ・Standalone data
Number of Products Registered Worldwide
products ・Standalone data
Cephalosporin Plant (Ethiopia) Installed Capacity
million vials per annum ・Standalone data
Number of Products Under Registration
products ・Standalone data
Khopoli/Pen Greenfield Project Planned Capacity - Oral Tablets
million tablets per annum ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
69.23% 69.23% 69.23% 69.23% 69.23% 69.23% 69.23% 69.23% 63.77% 63.77% 63.77% 63.77%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.12%
30.78% 30.76% 30.77% 30.77% 30.77% 30.76% 30.77% 30.77% 36.22% 36.23% 36.22% 36.11%
No. of Shareholders 9,0029,0629,5259,6209,92010,1399,74910,37910,92912,04311,78512,627

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Concalls